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Abstract
The synthesis of peptide-luciferin conjugates has a pivotal role in the development of bioluminescent detection systems that 
are based on the determination of protease enzyme activity. This work describes the optimized synthesis of an N-peptide-
6-amino-d-luciferin conjugate (Fmoc-Gly-Pro-6-amino-d-luciferin) with a simple fragment condensation method in adequate 
yields. Fmoc-Gly-Pro-6-amino-d-luciferin was produced from a previously synthesized Fmoc-Gly-Pro-OH and also previ-
ously synthesized 6-amino-2-cyanobenzothiazole with an optimized method, to which conjugate cysteine was added in an 
also improved way. The resulting conjugate was successfully used in a bioluminescent system, in vitro, demonstrating the 
applicability of the method.
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Introduction
Bioluminescent detection systems, used for in vivo and 
in vitro analytical methods, have been in the spotlight of 
research in the past decades (Jiang et al. 2018; Xu et al. 
2016; Sadikot and Timothy 2005; Chollet and Ribault 
2012; Sato et  al. 2004). The advantage of these sys-
tems over fluorescent systems lies in their superior sen-
sitivity and easy handling (De Saint-Hubert et al. 2012; 
Hu et al. 2012). The most ubiquitous enzyme-substrate 
system in bioimaging is the American firefly (Photinus 
pyralis) luciferin-luciferase system (Presiado et al. 2012; 
Zhang et al. 2012). Substituting this luciferin’s 6-position 
hydroxyl group with an amino group, the resulting ami-
noluciferin (aLuc) can form amide bond with a peptide, 
while retaining the transport and bioluminescent proper-
ties of the original substrate, resulting in a good substrate 
for different important proteases, which can be used for 
the determination of the enzymatic activity (White et al. 
1966).
Earlier this year a general synthesis method for N-pep-
tide-6-amino-d-luciferin conjugates, via a hybrid liquid/
solid phase method, was published (Kovács et al. 2018). 
The applicability of the strategy was demonstrated with 
the preparation of a known substrate (O’Brian et al. 2005; 
Hickson et al. 2010), N-Z-Asp-Glu-Val-Asp-6-amino-d-lu-
ciferin (N-Z-DEVD-aLuc, Z: benzyloxycarbonyl) used to 
measure the activity of caspase-3, and consequently the 
efficiency of apoptosis-inducing drugs. Our goal was to 
use the same strategy to produce N-Z-Gly-Pro-6-amino-
d-luciferin (N-Z-GP-aLuc), which can be used to measure 
the activity of other protease enzymes, namely Fibroblast 
activation protein alpha (FAP) and Prolyl Oligopeptidase 
(POP/PREP), two prolyl-specific serine proteases, the lev-
els of which are elevated in many cancers and may have 
roles in promoting angiogenesis and in immunotolerant 
tumour microenvironment (Christiansen et al. 2013).
Literary Background
Synthesis routes of peptide-6-amino-d-luciferin conju-
gates have been published five times. The backgrounds 
were worked out by Geiger and Miska (1991), who 
developed four methods (phospho-azo and mixed anhy-
dride methods, both with both 6-amino-2-cyanoben-
zothiazole and carboxyl protected 6-amino-d-luciferin 
as starting material) and produced 13 different conju-
gates. The mixed anhydride/6-amino-2-cyanobenzo-
thiazole method was modified in a 2003 Promega pat-
ent (O’Brian et al. 2003), and by Gryshuk et al. (2011). 
O’Brian et  al. (2005) followed a different path, when 
6-amino-2-cyanobenzothiazole was coupled with a pro-
tected peptide with the help of DCC and HOBt. Kovács 
et al. (2018) synthetized a conjugate with a different, liq-
uid/solid phase synthesis method with better yields than 
the other methods (unfortunately, in some cases yields and 
conversion rates were not determined in the literature and 
the cited patents, also, HPLC, MS and NMR analysis is 
incomplete or missing (Tables S1–S4)).
Unsuccessful Attempt
Our original plan was to synthesize N-Z-GP-aLuc, apply-
ing the above-mentioned 2018 method (Kovács et al. 2018). 
First the key molecule, 6-amino-2-cyanobenzothiazole (1) 
was produced (Kovács et al. 2018) which was then coupled 
to Fmoc-Pro-OH (Fmoc: 9-fluorenylmethoxycarbonyl). 
The resulting protected amino acid-heterocycle conjugate 
(Fmoc-Pro-6-amino-2-cyanobenzothiazole, 2, Figs. S1, S2) 
was reacted with d-cysteine. The structure of the resulting 
Fmoc-Pro-6-amino-d-luciferin was attested with 1H-NMR 
(Fig. S3) and 13C-NMR Fig. S4), LC-MS analysis was also 
carried out (Figs. S5, S6). Then the protected amino acid-
aminoluciferin conjugate was attached to p-alkoxybenzyl 
alcohol resin. However, attaching the protected amino acid-
aminoluciferin conjugate to solid support, the loading was 
only 50%. This meant that we had a significant loss of the 
conjugate, even though some of it can be regained with dif-
ferent purification methods and reused during further resin 
attachment. In order to reach higher load, instead of 3 h, the 
coupling reaction mixture was shaken for 6 h. The determi-
nation of load showed that no improvement was achieved in 
loading and, according to the resulting material’s RP-HPLC 
profile (Fig. S7) and the mass spectrum (MS) (Fig. S8), 20% 
of the coupled material was dehydrogenated among the con-
ditions mentioned above. As we were planning to purify the 
final, completed product, the synthetizing process was not 
abandoned. The product on the resin was Fmoc-deprotected, 
which was followed by coupling Z-protected glycine to the 
proline, and the resulting conjugate was cleaved from the 
resin (Kovács et al. 2018).
The RP-HPLC profile of the product (Fig. S9) showed a 
homogeneous material, but, according to the mass spectrum 
(Fig. S10), it was not the expected N-Z-GP-aLuc, but a fully 
dehydrogenated conjugate, N-Z-Gly-Pro-6-aminodehydrolu-
ciferin. This was also attested by its 1H-NMR-spectrum (Fig. 
S11), on which the α-proton of the 2-thiazoline ring was not 
detectable; however, an olefin proton was, as proof of dehy-
drogenation. The driving force behind this dehydrogenation 
was the aromatization of the 2-thiazoline ring, which led to 
its transformation into a thiazole ring (Fig. 1). Since this 
reaction did not occur earlier either, it might have been the 
result of the longer exposure to the basic conditions.
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As dehydroluciferin is a very efficient inhibitor of lucif-
erase (Ciuffreda et al. 2013; Fontes et al. 1997), it is not 
suitable for the above-mentioned measurement of enzymatic 
activity.
Therefore, our goal was to find a method that is more reli-
able than the hybrid liquid/solid phase synthesis method, a 
synthesis route that prevents the side reactions mentioned 
above. The problem was solved with returning to the frag-
ment-condensation method, which is used to avoid problems 
occurring during stepwise solid phase synthesis (Nyfeler 
1994). However, we had to make modifications to achieve 
better results than the standard method (O’Brian et al. 2005; 
Geiger and Miska 1991; O’Brian et al. 2003; Gryshuk et al. 
2011).
Results and Discussion
The desired peptide-luciferin conjugate (N-Fmoc-GP-
aLuc) was reached in a 2-step route:
(a) attachment of the target peptide sequence to 
6-amino-2-cyanobenzothiazole → (b) cysteine addition 
(Fig. 2, Table S5):
The optimized synthesis route of the key molecule 
and the modifications of the two steps make a significant 
improvement over the standard method.
Fig. 1  The unsuccessful synthesis route to produce the desired N-Z-Gly-Pro-6-amino-d-luciferin
Fig. 2  The 2-step synthetic route to N-Fmoc-GP-aLuc (3). Reagents and conditions: a Fmoc-Gly-Pro-OH, TCFH, dry DCM, DIPEA, overnight, 
rt, yield 68% b d-Cys∙HCl∙H2O, MeOH,  H2O, 5 m/m%  NaHCO3, 2 h, rt, yield 78%
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Synthesis of 6‑Amino‑2‑Cyanobenzothiazole (1)
We started with the synthesis of the key molecule, 6-amino-
2-cyanobenzothiazole (1) with an improved method (Kovács 
et al. 2018): commercially available 2-chlorobenzothiazole 
was nitrated with a mixture of cc  H2SO4 and  KNO3, at 0 °C 
(Katz 1951). The structure of the resulting 2-chloro-6-ni-
trobenzothiazole was attested by 1H-NMR spectrum (83% 
yield corresponding to the isolated pure product). In the next 
step the nitro group was reduced with ethyl acetate/water/
ammonium chloride/iron powder in a Soxhlet extractor with 
a good yield (88%, corresponding to the crude product). The 
chlorine/nitrile exchange in the 6-amino-2-chlorobenzothi-
azole was carried out in N,N-dimethylacetamide (DMAA), 
a polar aprotic non-aqueous solvent, with KCN, at high 
temperature (110 °C) in 12 h, resulting in relatively high 
yield (78%, corresponding to the crude product). During 
procession the remaining KCN was reacted with  KH2PO4, 
keeping pH above 7 to avoid the production of HCN, then 
first  FeSO4 was added, forming  K4[Fe(CN)6], then Fe(III) 
salt was added, forming insoluble Berlin blue, which can 
be filtered from the solution. The product was purified with 
recrystallization (Kovács et al. 2018).
Synthesis 
of Fmoc‑Gly‑Pro‑6‑Amino‑2‑Cyanobenzothiazole (2)
A suitably protected, commercially purchased peptide, 
Fmoc-Gly-Pro-OH, was coupled with the key molecule, 
6-amino-2-cyanobenzothiazole (1). (As during the syn-
thesis only a dipeptide was coupled to the 6-amino-2-cy-
anobenzothiazole (1), it was reasonable to purchase a ready 
material, rather than synthesize and purify one. In case of 
longer peptides, solid phase peptide synthesis can be used.) 
Due to the deactivated amino group of the 6-amino-2-cy-
anobenzothiazole (1), the amide bond could not be formed 
with the usual coupling reagents; therefore, a more powerful 
coupling agent (Carpino et al. 1996) was necessary. Excel-
lent conversion (97%) of the 6-amino-2-cyanobenzothiazole 
was obtained with 1.5 equivalents of chloro-N,N,N′,N′-
tetramethylformamidinium hexafluorophosphate (TCFH) 
(Kovács et al. 2018). Obtained yield, corresponding to the 
crude product: 68%. (Figs. S12, S13).
With this process, we could avoid the extremely long cou-
pling time of the standard mixed anhydride method (O’Brian 
et al. 2003; Gryshuk et al. 2011) and reached adequate 
conversion/yield.
Synthesis of Fmoc‑Gly‑Pro‑6‑Amino‑d‑Luciferin (3)
The peptide-heterocycle conjugate (Fmoc-Gly-Pro-6-amino-
2-cyanobenzothiazole, 2) was dissolved in methanol 
(MeOH), then d-cysteine hydrochloride monohydrate was 
added. The resulting substance was dissolved in water and 
the cysteine was released from its salt with  NaHCO3. During 
the reaction (about 25 min) the pH of the solution was kept 
between 7.3 and 7.4 with the addition of  NaHCO3 aque-
ous solution, the process was continuously monitored with 
a pH-meter, under argon atmosphere. The Fmoc-protection 
of the the N-terminal amino-group of the peptide was kept 
up because it gave higher biological stability to the conju-
gate. The structure of the resulting conjugate was attested 
with 1H-NMR (Fig. S14), 13C-NMR (Fig. S15) and LC-MS 
(Figs. S16, S17).
This method is also an improvement over the standard 
practice (O’Brian et  al. 2005; Geiger and Miska 1991; 
O’Brian et al. 2003; Gryshuk et al. 2011) as the window 
between pH 7.3–7.4 a, rules out racemization b, ensures the 
release of the cysteine from its salt.
Analysis of Fmoc‑Gly‑Pro‑6‑Amino‑d‑Luciferin (3) 
in Enzyme Activity Assays
The product (3) was tested in bioluminescent-based enzyme 
activity assays. The substrate specificity of N-Fmoc-GP-
aLuc was measured with two human proteases that are 
involved in cancer, POP/PREP and FAP, and with a bacte-
rial non-specific endoproteinase Pro-C. All three enzymes 
accepted the substrate and liberated aminoluciferin as a 
product resulting in increased luminescence signal (Fig. 3). 
Enzymatic degradation was confirmed with protease inhib-
itor, which completely abolished bioluminescent signal 




TCFH and d-Cys·HCl·H2O were obtained from AK Scien-
tific Inc. (Union City, CA, USA). Fmoc-Gly-Pro-OH was 
purchased from Iris Biotech GmbH (Marktredwitz, Ger-
many). Trifluoroacetic acid (TFA) gradient grade came from 
VWR International (Radnor, PA, USA). POP/PREP and 
recombinant human FAP alpha were obtained from R&D 
Systems (Minneapolis, MN, USA). Endoproteinase Pro-C, 
DTT and Bovine Serum Albumin (BSA) were purchased 
from Sigma–Aldrich (St. Louis, MO, USA), black plastic 
microtiter plates were from Tomtec (Budapest, Hungary). 
Complete protease inhibitor cocktail was from Roche Basel, 
Switzerland and Luminescence Detection Reagent was from 
Promega (Madison, WI, USA).
TLC was performed on silica gel plates 60  F254 from 
Merck (Darmstadt, Germany). pH values were measured 
with a Hanna HI 8424 pH meter. Analytical reversed-phase 
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high-performance liquid chromatography (RP-HPLC) was 
performed on an Agilent 1200 series separations module 
with diode array and multiple wavelength detector (Wald-
bronn, Germany), with a Luna C18(2) 100  Å column 
(10 µm, 250 × 4.6 mm) Phenomenex, (Torrance, CA, USA). 
The experiments were carried out at room temperature (rt) 
with a flow rate maintained at 1.2 mL min−1 at 220 nm wave-
length (mobile phases solvent A: 0.1% TFA in Milli-Q water 
and solvent B: 0.1% TFA in acetonitrile (AcN)) using gradi-
ent elution. Separation was achieved on a Shimadzu (Kyoto, 
Japan) semi-preparative system with a Jupiter C18 300 Å 
column (10 µm, 250 × 21.20 mm), also from Phenomenex 
(mobile phases solvent A: 0.1% TFA in Milli-Q water and 
solvent B: 0.1% TFA in AcN) using gradient elution. Mass 
spectrometry data were collected on Waters (Milford, MA, 
USA) SQ Detector with atmospheric pressure ionization 
(API) mass spectrometer in positive ion mode; 1H NMR and 
13C NMR spectra were recorded using a Bruker DR X 500 
spectrometer at 600 MHz and 150 MHz, in deuterated dime-
thyl sulfoxide ([D6]DMSO). Chemical shifts were reported 




2.03 g (5.145 mmol, 1.5 equiv) anhydrous (anh) Fmoc-
Gly-Pro-OH and 1.44 g (5.145 mmol, 1.5 equiv) anh TCFH 
were solved in 7 mL anh dichloromethane (DCM). The 
mixture was stirred for 60 min at room temperature. First 
1 mL (6.174 mmol, 1.8 equiv) N,N-diisopropylethylamine 
(DIPEA), then 0.600 g (3.43 mmol, 1 equiv) anh 6-amino-
2-cyanobenzothiazole (1) was added. After stirring the 
reaction mixture overnight at room temperature (according 
to HPLC analysis the conversion was 97%), it was washed 
with water (2 × 7 mL), with saturated  NaHCO3-solution 
(2 × 7 mL), then with water again (2 × 7 mL), and finally 
with saturated NaCl-solution (2 × 7 mL). It was dried over 
sicc  Na2SO4, finally concentrated in vacuo. The resulting 
crude material was a pale yellow powder, its weight was 
1.28 g, yield corresponding to the crude product: 68%. m/z 
[M + H]+ calcd for  C30H25N5O4S 551.62, found 552.0 (Fig. 
S12). RP-HPLC (for the purified compound): 50–100% 
B in 25 min + 3 min up to 100% B + 100% B in 5 min, 
 tR1 = 8.973  min: Fmoc-Gly-Pro-OH,  tR2 = 17.868  min: 
Fmoc-Gly-Pro-6-amino-2-cyanobenzothiazole (Fig. S13).
Synthesis of Fmoc-Gly-Pro-6-Amino-d-Luciferin (3)
5.512  g (0.010  mol, 1 equiv.) Fmoc-Gly-Pro-6-amino-
2-cyanobenzothiazole (2) was dissolved in 25 mL MeOH. 
2.634 g (0.015 mol, 1.5 equiv.) d-cysteine∙HCl∙H2O, solved 
in 19 mL distilled water, was added to the solution at room 
temperature, under argon atmosphere, then the mixture was 
stirred continuously under pH control (starting pH: 2.27).
After 20 min’ stirring at room temperature, 30 mL, 5% 
(m/m)  NaHCO3 was added dropwise over a period of 1 h to 
the mixture in order to release cysteine from its salt, while 
checking pH continuously. Reaching pH 2.6, a fine, yellow 
Fig. 3  Luminescence is proportional to protease activity and 
N-Fmoc-GP-aLuc concentration. Different amount of a POP/PREP, 
b FAP and c Endoproteinase Pro-C proteases were titrated and 
assayed with 1–100 µmol N-Fmoc-GP-aLuc for 2 h. (d–f) The effect 
of protease inhibition was tested using the Complete protease inhibi-
tor cocktail, in each reaction with 10  µmol N-Fmoc-GP-aLuc and 
32  pmol/min/reaction protease activity. Each point represents the 
average of 3 wells ± SD. Values are blank-subtracted (blank = no pro-
tease). *p < 0.05; **p < 0.01; ***p < 0.001
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solid material, Fmoc-Gly-Pro-6-amino-d-luciferin free car-
boxylic acid, started to precipitate. At pH 6.3, this material 
started to dissolve, and at pH 7.40, it dissolved completely. 
Here the Fmoc-Gly-Pro-6-amino-d-luciferin formed Na-salt, 
which dissolved under these conditions.
After another 20 min’ stirring at room temperature, the 
organic solvent was evaporated. From the remaining aque-
ous solution, a pale yellow solid material, Fmoc-Gly-Pro-
6-amino-d-luciferin Na-salt precipitated partly. This aque-
ous mixture was extracted with 3 × 15 mL ethyl acetate, in 
order to get rid of possible impurities. The combined organic 
layers were extracted with saturated NaCl solution. Hav-
ing dropped the resulting solution on a mixture of ice and 
cc HCl, a fine yellow precipitate, Fmoc-Gly-Pro-6-amino-
d-luciferin free carboxylic acid, formed. It was allowed 
to settle for 10 min, filtered and washed with 2 × 5 mL 
water, then air-dried to constant weight, which was 5.115 g 
(7.80 mmol), yield corresponding to the crude product: 
78%. 1H NMR (500 MHz, [D6]DMSO) δ 10.39 (s, 1H), 
8.59 (t, J = 15.85 Hz, 1H), 8.09 (d, J = 8.98 Hz, 1H), 7.88 
(d, J = 7.43 Hz, 2H), 7.71 (d, J = 7.48 Hz, 2H), 7.66–7.60 
(m, 1H), 7.48 (t, J = 5.65 Hz, 1H), 7.39 (q, J1 = 7.60 Hz, 
J2 = 15.29 Hz, 2H), 7.30 (q, J1 = 6.78 Hz, J2 = 13.76 Hz, 
2H), 5.43 (t, J = 8.98  Hz, 1H), 4.47 (dd, J1 = 2.92  Hz, 
J2 = 5.21 Hz, 1H), 4.29–4.25 (m, 1H), 4.21 (q, J1 = 6.68 Hz, 
J2 = 14.87 Hz, 1H), 3.95–3.67 (m, 4H), 3.65–3.48 (m, 4H), 
2.20–2.11 (m, 1H), 2.06–1.99 (m, 1H), 1.97–1.88 (m, 2H) 
(Fig. S14). 13C NMR (125 MHz, [D6]DMSO) δ 171.15, 
171.05, 167.43, 164.43, 159.04, 156.55, 148.58, 143.86, 
140.70, 138.38, 136.28, 127.61, 127.08, 125.27, 124.20, 
120.10, 119.64, 111.52, 78.11, 65.70, 60.47, 46.62, 45.92, 
42.72, 34.78, 29.28, 24.52 (Figure S15). m/z [M + H]+ calcd 
for  C33H29N5O6S2 655.74 found 656.0 (Figure S16). RP-
HPLC: 70–100% B in 15 min,  tR= 12.608 min. TLC: tolu-
ene/EtOH 50:30 saturated with water, Rf: 0.44.
Purification of Crude Fmoc-Gly-Pro-6-Amino-d-Luciferin (3)
160 mg crude peptide (45% desired material content, 72 mg) 
was dissolved in 1 mL N,N-dimethylformamide (DMF), then 
filtered, using a 0.45∝ m nylon filter. Gradient elution was 
used, 40–70% eluent B in 60 min at a 4 mL  min−1 flow rate 
with detection at 220 nm. Pure fractions were collected and 
lyophilized to give a pale yellow material, the weight of 
which was 23 mg (0.035 mmol), yield corresponding to the 
isolated pure product: 32%.
Fmoc-Gly-Pro-aLuc Assay
The following proteases were used in the assay: recom-
binant human POP/PREP, recombinant human FAP 
and Endoproteinase Pro-C at equivalent protease activ-
ity in tenfold serial dilution starting from 32 fmol/min/
reaction to 320 pmol/min/reaction. Assay buffer for POP/
PREP and Endoproteinase Pro-C contained 25  mmol 
tris(hydroxymethyl)aminomethane HCl-salt (Tris∙HCl) pH 
7.4, 250 mmol NaCl, 2.5 mmol 1,4-dithiothreitol (DTT) 
and the assay buffer for FAP contained 50 mmol Tris∙HCl 
pH 7.4, 1 M NaCl, 1 mg/mL BSA. The N-Fmoc-GP-aLuc 
substrate was applied in 1 µmol to 100 µmol in 25 µL final 
reaction volume in a black plastic microtiter plate. The 
effect of protease inhibition (Complete protease inhibitor 
cocktail) was prepared by dissolving one tablet in 2 mL 
POP/PREP buffer and used in 2.5-fold dilution in each 
reaction with 10 µmol N-Fmoc-GP-aLuc and 32 pmol/min/
reaction protease activity. After 2 h incubation at 37 °C 
25 µL Luminescence Detection Reagent was added to each 
well. Luminescence was recorded within 5 min. The blank 
wells contained each component except proteases. Pre-
sented values are blank-subtracted.
Statistics
Statistical significance was calculated by unpaired t-test 
(two-tailed, homoscedastic) between untreated and inhibi-
tor containing samples.
Conclusion
We have developed an improved route for the synthesis of 
N-peptid-6-amino-d-luciferin conjugates. The method is 
more reliable than the standard practice as the preparation 
of one of the building blocks and two operations have been 
improved, which has led to better yields and significantly 
faster production time. The produced N-Fmoc-GP-aLuc was 
successfully used to measure FAP and POP/PREP enzyme 
activity in vitro.
This optimized method provides a practical and scalable 
way for the preparation of other N-peptide-6-amino-d-lucif-
erin conjugates as well.
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